




RECEIVED
MAR 13 2009

09 MAR 13 AM 6: 02


DuPont Haskell Global Centers
for Health and Environmental Sciences
1090 Elkton Road, P.O. Box 50
Newark, DE 19714-0050

March 11, 2009

Via Federal Express



Document Processing Center (Mail Code 7407M)
Room 6428
Attention: 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency, ICC Building
1201 Constitution Ave., NW
Washington, DC 20004



Dear 8(e) Coordinator:

N-Acetyl-L-Aspartate
CAS # 997-55-7

This letter is to inform you of the results of an acute oral toxicity study in rats with the test substance referenced above.

A single dose of test substance in deionized water was administered by oral gavage to groups of 5 fasted male and 5 fasted female CrI:CD(SD) rats at a dose of 2000 or 5000 mg/kg of body weight. The rats were observed for mortality, body weight effects, and clinical signs for up to 14 days after dosing. The rats were given a complete gross pathological examination to detect any grossly observable evidence of organ or tissue damage or dysfunction.

No test substance-related clinical signs were observed in male rats dosed at 2000 mg/kg. Three female rats dosed at 2000 mg/kg exhibited ear twitching on the day of dosing. One of these rats also exhibited arching of the back during handling on the day of dosing. No biologically important body weight losses occurred after dosing in male or female rats dosed at 2000 mg/kg. No test substance-related gross lesions were observed in males or females dosed at 2000 mg/kg.

Four of five female rats dosed at 5000 mg/kg were found dead 1 or 2 days after dosing. No other deaths occurred. These four female rats exhibited clinical signs including high carriage, clear ocular discharge, lethargy, paleness, absent feces, splayed limb, or ataxia. No clinical signs were observed in the remaining female rat dosed at 5000 mg/kg. The surviving female rat dosed at 5000 mg/kg exhibited no body weight loss after dosing and gained weight relative to the fasted weight. Male rats dosed at 5000 mg/kg exhibited clinical signs including ataxia (1/5 rats on day of dosing), abnormal gait and/or high carriage (3/5 rats on the day of dosing and for up to 2-3 days post dosing), paleness, absent feces, stained fur/skin, breathing noise, or diarrhea. One male rat dosed at 5000 mg/kg had weight loss of approximately 5% of the fasted weight by test day 2 and another had weight loss of approximately 14% of initial weight by test day 4. However, all male rats dosed at 5000 mg/kg gained weight at the end of the study relative to their fasted weights on test day 0. No test substance-related gross lesions were observed in males or females dosed at 5000 mg/kg.

Contains No CBI

CONTAINS NO CBI

317791

Although it is not clear that this study is subject to TSCA 8(e) reporting requirements, this information is submitted as a precautionary measure and because it is information in which EPA may have an interest.

Sincerely,

A handwritten signature in black ink that reads "A. Michael Kaplan". The signature is fluid and cursive, with a long horizontal stroke at the end.

A. Michael Kaplan, Ph.D.
Director - Regulatory Affairs

AMK/CC: clp
(302) 366-5260